Further evaluation of the role of machine learning in improving HCC risk prediction models is warranted, but it is likely that the combination of machine learning models with more predictive biomarkers such as AFP-L3 and DCP will provide the next significant improvement in prediction model performance. This evidence concerns the gene AFP and hepatocellular carcinoma.